Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores

Journal of Clinical Oncology

Volumn 35, Issue 20, 2017, Pages 2240-2250

  Lecarpentier, Julie ^a   Kuchenbaecker, Karoline B ^a,b   Barrowdale, Daniel ^a   Dennis, Joe ^a   McGuffog, Lesley ^a   Leslie, Goska ^a   Lee, Andrew ^a   Al Olama, Ali Amin ^a   Tyrer, Jonathan P ^a   Frost, Debra ^a   Ellis, Steve ^a   Easton, Douglas F ^a   Antoniou, Antonis C ^a   Tischkowitz, Marc ^c   Evans, D Gareth ^d   Henderson, Alex ^e   Brewer, Carole ^f   Eccles, Diana ^g   Cook, Jackie ^h   Ong, Kai Ren ⁱ   Walker, Lisa ^j   Side, Lucy E ^k   Hodgson, Shirley ^l   Izatt, Louise ^m   Eeles, Ros ⁿ   Orr, Nick ^o   Porteous, Mary E ^p   Davidson, Rosemarie ^q   Adlard, Julian ^r   Silvestri, Valentina ^s   Rizzolo, Piera ^s   Navazio, Anna Sara ^s   Valentini, Virginia ^s   Zelli, Veronica ^s   Ottini, Laura ^s   Toss, Angela ^t   Medici, Veronica ^t   Cortesi, Laura ^t   Zanna, Ines ^u   Palli, Domenico ^u   Radice, Paolo ^v   Manoukian, Siranoush ^v   Peissel, Bernard ^v   Azzollini, Jacopo ^v   Peterlongo, Paolo ^w   Viel, Alessandra ^x   Cini, Giulia ^x   Damante, Giuseppe ^y   Tommasi, Stefania ^z   Alducci, Elisa ^aa   Tognazzo, Silvia ^aa   Montagna, Marco ^aa   Caligo, Maria A ^ab   Soucy, Penny ^ac   Simard, Jacques ^ac   Mulligan, Anna Marie ^ad   Andrulis, Irene L ^ad,ae   Glendon, Gord ^ae   Southey, Melissa ^af   Campbell, Ian ^af,ah   James, Paul ^af,ah   Mitchell, Gillian ^af,ah   Spurdle, Amanda B ^ag   Holland, Helene ^ag   Chenevix Trench, Georgia ^ag   John, Esther M ^ai   Steele, Linda ^aj   Ding, Yuan Chun ^aj   Neuhausen, Susan L ^aj   Weitzel, Jeffrey N ^aj   Conner, Thomas A ^ak   Buys, Saundra S ^ak   Goldgar, David E ^al   Godwin, Andrew K ^am   Sharma, Priyanka ^am   Rebbeck, Timothy R ^an   Vijai, Joseph ^ao   Robson, Mark ^ao   Lincoln, Anne ^ao   Musinsky, Jacob ^ao   Gaddam, Pragna ^ao   Offit, Kenneth ^ao   Loud, Jennifer T ^ap   Greene, Mark H ^ap   Toland, Amanda Ewart ^aq   Senter, Leigha ^aq   Huo, Dezheng ^ar   Nielsen, Sarah M ^ar   Olopade, Olufunmilayo I ^ar   Nathanson, Katherine L ^as   Domchek, Susan M ^as   Lorenchick, Christa ^at   Jankowitz, Rachel C ^at   Couch, Fergus J ^au   Janavicius, Ramunas ^av   Hansen, Thomas V O ^aw   Bojesen, Anders ^ax   Nielsen, Henriette Roed ^ax   Skytte, Anne Bine ^ay   Sunde, Lone ^ay   Jensen, Uffe Birk ^ay   Pedersen, Inge Sokilde ^az   Krogh, Lotte ^ba   Kruse, Torben A ^ba   Thomassen, Mads ^ba   Osorio, Ana ^bb   De La Hoya, Miguel ^bc   Garcia Barberan, Vanesa ^bc   Caldes, Trinidad ^bc   Segura, Pedro Perez ^bc   Balmaña, Judith ^bd   Gutiérrez Enríquez, Sara ^be   Diez, Orland ^be,bf   Teulé, Alex ^bg   Del Valle, Jesús ^bg   Feliubadalo, Lidia ^bg   Pujana, Miquel Angel ^bg   Lazaro, Conxi ^bg   Izquierdo, Angel ^bg   Darder, Esther ^bg   Brunet, Joan ^bg   Fostira, Florentia ^bh   Hamann, Ute ^bi   Sutter, Christian ^bj   Meindl, Alfons ^bk   Ditsch, Nina ^bl   Gehrig, Andrea ^bm   Dworniczak, Bernd ^bn   Engel, Christoph ^bo   Wand, Dorothea ^bp   Niederacher, Dieter ^bq   Steinemann, Doris ^br   Hahnen, Eric ^bs   Hauke, Jan ^bs   Rhiem, Kerstin ^bs   Wappenschmidt, Barbara ^bs   Schmutzler, Rita K ^bs   Kast, Karin ^bt   Arnold, Norbert ^bu   Wang Gohrke, Shan ^bv   Lasset, Christine ^bw   Damiola, Francesca ^bw   Barjhoux, Laure ^bw   Mazoyer, Sylvie ^bx   Stoppa Lyonnet, Dominique ^by   Belotti, Muriel ^by   Van Heetvelde, Mattias ^bz   Poppe, Bruce ^bz   De Leeneer, Kim ^bz   Claes, Kathleen B M ^bz   Kiiski, Johanna I ^ca,cb   Khan, Sofia ^ca,cb   Nevanlinna, Heli ^ca,cb   Aittomaki, Kristiina ^cb   Vvan Asperen, Christi J ^cc   Vaszko, Tibor ^cd   Kasler, Miklos ^cd   Olah, Edith ^cd   Arason, Adalgeir ^ce   Agnarsson, Bjarni A ^ce   Johannsson, Oskar Th ^ce   Barkardottir, Rosa B ^ce   Teixeira, Manuel R ^cf,cg   Pinto, Pedro ^cf   Lee, Jong Won ^ch   Lee, Min Hyuk ^ci   Lee, Jihyoun ^ci   Kim, Sung Won ^cj   Kang, Eunyoung ^cj   Park, Sue Kyung ^ck   Kim, Zisun ^ci   Tan, Yen Y ^cl   Berger, Andreas ^cl   Singer, Christian F ^cl   Yoon, Sook Yee ^cm   Teo, Soo Hwang ^cm   Von Wachenfeldt, Anna ^cn   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

ⁱ BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^j CHURCHILL HOSPITAL   (United Kingdom)

^k GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^l ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^m GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^p WESTERN GENERAL HOSPITAL   (United Kingdom)

^q QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^r CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^s SAPIENZA UNIVERSITY OF ROME   (Italy)

^t UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^u CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^v Fondazione Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS)   (Italy)

^w FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^x CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^y UNIVERSITY OF UDINE   (Italy)

^z NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^aa VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^ab UNIVERSITY HOSPITAL OF PISA   (Italy)

^ac Université Laval   (Canada)

^ad UNIVERSITY OF TORONTO   (Canada)

^ae MOUNT SINAI HOSPITAL   (Canada)

^af UNIVERSITY OF MELBOURNE   (Australia)

^ag QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^ah PETER MACCALLUM CANCER CENTRE   (Australia)

^ai CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^aj CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^ak UNIVERSITY OF UTAH   (United States)

^al UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^am UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^an DANA FARBER CANCER INSTITUTE   (United States)

^ao MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ap NATIONAL CANCER INSTITUTE   (United States)

^aq OHIO STATE UNIVERSITY   (United States)

^ar UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^as UNIVERSITY OF PENNSYLVANIA   (United States)

^at UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^au MAYO CLINIC   (United States)

^av State Research Institute Innovative Medicine Center   (Lithuania)

^aw Rigshospitalet   (Denmark)

^ax LILLEBAELT HOSPITAL   (Denmark)

^ay AARHUS UNIVERSITY HOSPITAL   (Denmark)

^az AALBORG UNIVERSITY HOSPITAL   (Denmark)

^ba ODENSE UNIVERSITY HOSPITAL   (Denmark)

^bb National Cancer Research Centre and Spanish Network on Rare Diseases   (Spain)

^bc HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^bd University Hospital ^*  (Spain)

^be VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^bf HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^bg CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^bh INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^bi GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^bj UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^bk TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^bl UNIVERSITY OF MUNICH   (Germany)

^bm UNIVERSITY OF WÜRZBURG   (Germany)

^bn UNIVERSITY OF MÜNSTER   (Germany)

^bo UNIVERSITY OF LEIPZIG   (Germany)

^bp UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^bq UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^br HANNOVER MEDICAL SCHOOL   (Germany)

^bs UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^bt UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^bu UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^bv UNIVERSITY HOSPITAL ULM   (Germany)

^bw CENTRE LÉON BÉRARD   (France)

^bx UNIVERSITÉ DE LYON   (France)

^by INSTITUT CURIE   (France)

^bz GHENT UNIVERSITY   (Belgium)

^ca UNIVERSITY OF HELSINKI   (Finland)

^cb HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^cc LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^cd NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^ce LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^cf PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^cg UNIVERSITY OF PORTO   (Portugal)

^ch Asan Medical Center   (South Korea)

^ci Soonchunhyang University   (South Korea)

^cj The Catholic University of Korea   (South Korea)

^ck Seoul National University   (South Korea)

^cl MEDICAL UNIVERSITY OF VIENNA   (Austria)

^cm Sime Darby Technology Center   (Malaysia)

^cn KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

AGE; AGED; AREA UNDER THE CURVE; CANCER RISK; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; ADULT; BREAST TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HETEROZYGOTE; MIDDLE AGED; MULTIFACTORIAL INHERITANCE; MUTATION; PROCEDURES; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; CASE-CONTROL STUDIES; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MULTIFACTORIAL INHERITANCE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 85024491245     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.4935     Document Type: Conference Paper

References (46)

1. Castro E, Eeles R: The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 14: 409-414, 2012
2. Rizzolo P, Silvestri V, Tommasi S, et al: Male breast cancer: Genetics, epigenetics, and ethical aspects. Ann Oncol 24:viii75-viii82, 2013 (suppl 8)
3. Kote-Jarai Z, Leongamornlert D, Saunders E, et al: BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer 105:1230-1234, 2011
4. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al: Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106:1697-1701, 2012
5. Basham VM, Lipscombe JM, Ward JM, et al: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4:R2, 2002
6. Cancer Research UK: Cancer incidence for common cancers. http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/
7. Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316, 1999
8. Thompson D, Easton DF; Breast Cancer Linkage Consortium: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002
9. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al: Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J Med Genet 42:711-719, 2005
10. Tai YC, Domchek S, Parmigiani G, et al: Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99:1811-1814, 2007
11. Al Olama AA, Kote-Jarai Z, Berndt SI, et al: A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46: 1103-1109, 2014
12. Michailidou K, Beesley J, Lindstrom S, et al: Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 47:373-380, 2015
13. Pashayan N, Duffy SW, Chowdhury S, et al: Polygenic susceptibility to prostate and breast cancer: Implications for personalised screening. Br J Cancer 104:1656-1663, 2011
14. Amin Al Olama A, Benlloch S, Antoniou AC, et al: Risk analysis of prostate cancer in PRACTICAL, a multinational consortium, using 25 known prostate cancer susceptibility loci. Cancer Epidemiol Biomarkers Prev 24:1121-1129, 2015
15. Mavaddat N, Pharoah PD, Michailidou K, et al: Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107:djv036, 2015
16. Orr N, Lemnrau A, Cooke R, et al: Genomewide association study identifies a common variant in RAD51B associatedwith male breast cancer risk. Nat Genet 44:1182-1184, 2012
17. Orr N, Cooke R, Jones M, et al: Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men. PLoS Genet 7:e1002290, 2011
18. Ottini L, Silvestri V, Saieva C, et al: Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: Results from a multicenter study in Italy. Breast Cancer Res Treat 138:861-868, 2013
19. Silvestri V, Rizzolo P, Scarno M, et al: Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. Eur J Cancer 51:2289-2295, 2015
20. Gaudet MM, Kuchenbaecker KB, Vijai J, et al: Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet 9: e1003173, 2013
21. Couch FJ, Wang X, McGuffog L, et al: Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 9:e1003212, 2013
22. Bojesen SE, Pooley KA, Johnatty SE, et al: Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45:371-384, 384e1-2, 2013
23. Silvestri V, Barrowdale D, Mulligan AM, et al: Male breast cancer in BRCA1 and BRCA2 mutation carriers: Pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 18:15, 2016
24. Rebbeck TR, Mitra N, Wan F, et al: Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313: 1347-1361, 2015
25. Dunning AM, Michailidou K, Kuchenbaecker KB, et al: Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet 48:374-386, 2016
26. Couch FJ, Kuchenbaecker KB, Michailidou K, et al: Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun 7:11375, 2016
27. Michailidou K, Hall P, Gonzalez-Neira A, et al: Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45:353-361, 361e1-2, 2013
28. Lin WY, Camp NJ, Ghoussaini M, et al: Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet 24: 285-298, 2015
29. Ghoussaini M, Edwards SL, Michailidou K, et al: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun 4:4999, 2014
30. French JD, Ghoussaini M, Edwards SL, et al: Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through longrange enhancers.AmJ Hum Genet 92:489-503, 2013
31. Meyer KB, O'Reilly M, Michailidou K, et al: Fine-scale mapping of the FGFR2 breast cancer risk locus: Putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet 93:1046-1060, 2013
32. Amin Al Olama A, Dadaev T, Hazelett DJ, et al: Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet 24:5589-5602, 2015
33. Antoniou AC, Beesley J, McGuffog L, et al: Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 70:9742-9754, 2010
34. Kuchenbaecker KB, McGuffog L, Barrowdale D, et al: Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (in press)
35. Eeles RA, Olama AA, Benlloch S, et al: Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45:385-391, 391e1-2, 2013
36. Kote-Jarai Z, Olama AA, Giles GG, et al: Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43:785-791, 2011
37. Gudmundsson J, Sulem P, Manolescu A, et al: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39:631-637, 2007
38. Eeles RA, Kote-Jarai Z, Giles GG, et al: Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316-321, 2008
39. National Comprehensive Cancer Network: NCCN guidelines genetic/familial high-risk assessment: Breast and ovarian, version 2.2016. http://www.nccn.org
40. National Institute for Clinical Excellence (NICE): Familial breast cancer: Classification, care and managing breast cancer and related risks in peoplewith a family history of breast cancer (CG164). https://www.nice.org.uk/guidance/cg164
41. Bancroft EK, Page EC, Castro E, et al: Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study. Eur Urol 66:489-499, 2014
42. Erratum: Eur Urol 67:e126, 2015
43. Pashayan N, Pharoah PD, Schleutker J, et al: Reducing overdiagnosis by polygenic risk-stratified screening: Findings from the Finnish section of the ERSPC. Br J Cancer 113:1086-1093, 2015
44. Pashayan N, Duffy SW, Neal DE, et al: Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet Med 17: 789-795, 2015
45. Gro?nberg H, Adolfsson J, AlyM, et al: Prostate cancer screening in men aged 50-69 years (STHLM3): A prospective population-based diagnostic study. Lancet Oncol 16:1667-1676, 2015
46. Macinnis RJ, Antoniou AC, Eeles RA, et al: A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancerwith potential clinical impact. Genet Epidemiol 35:549-556, 2011